BioWorld MedTech

Jan. 11, 2016

Diabetic Foot Ulcer Market: Omnigraft approval seen as catalyst for Integra, DFU market

A new FDA approval is expected to be an important catalyst for Integra Lifesciences Corp. (Plainsboro, N.J.) and represents a step in the right direction for the broader diabetic foot ulcer (DFU) market. Read More

Inside the Beltway: Hatch, Wyden urge CMS to redo PAMA reporting mandates

Call Me Maybe: Cardiac variants fail to predict risk in prospective study

TAVR provides fertile market for firm: Vivasure Medical picks up CE mark for percutaneous vascular closure device

MDD's Company Stock Report

Opponents say not a wise move: Indian government urged to rethink health care price caps

Daily M&A: S&N completes acquisition of Blue Belt Holdings for $275M

Patent Watch: Biomarker Strategies gains key patents for core technology

Products

People in Places

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for July 10, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Illustration of brain and brain waves, concept of focal seizure

Hyperexcitability may be joint problem in epilepsy, dementia

BioWorld

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...